Abbott, a healthcare conglomerate with businesses and products spanning diagnostics, medical devices, nutrition and more, announced the completion of its Exact Sciences acquisition. The transaction furthers Abbott’s reach into the cancer screening and diagnostics segments.
Exact Sciences has become a wholly-owned subsidiary of Abbott following the acquisition. Abbott has a team of over 122,000 people and serves more than 160 countries. Integrating Exact Sciences’ solutions and team into Abbott helps advance its mission of making healthcare more accessible and granting people more control over their health.
“Abbott’s global scale, track record of operational and commercial excellence and work with healthcare systems around the world will expand access to important tools for early cancer detection and personalized treatments,” Robert Ford, Abbott’s chairman and CEO, said in a statement. “With the legacy and deep expertise of the Exact Sciences team, we’re ready to transform cancer care.”
